OPKO Health (OPK) Announces Presentation of hGH-CTP Phase 2 Data; Response Comparison to Daily Genotropin Confirmed
Tweet Send to a Friend
OPKO Health (NYSE: OPK) presented clinical data from its completed 12-month hGH-CTP Phase 2 pediatric growth hormone deficiency clinical study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
